Pancreatic Cancer Research

ResearcherUniversitätsklinikum Knappschaftskrankenhaus BochumActive in the last 2 years

Stephan A. Hahn

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-0855-9741; OpenAlex author ID A5000633602. Sources: OpenAlex.

Their work

Papers
28 (first author 2, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
138
Papers, trials and grants by year

2012: 2 papers · 2013: 3 papers · 2014: 4 papers · 2015: 2 papers · 2016: none · 2017: 1 paper · 2018: none · 2019: none · 2020: 2 papers · 2021: 3 papers · 2022: 2 papers · 2023: 4 papers · 2024: 3 papers · 2025: 1 paper · 2026: 1 paper

Papers 28

  1. Author Correction: Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarc… Co-author DOI 10.1038/s41591-026-04234-8↗
  2. PLK1 blockade enhances the anti-tumor effect of MAPK inhibition in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.celrep.2025.115541↗
  3. Author Correction: Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarc… Co-author DOI 10.1038/s41591-024-03054-y↗
  4. An NFATc1/SMAD3/cJUN Complex Restricted to SMAD4-Deficient Pancreatic Cancer Guides Rational Therapies. Co-author DOI 10.1053/j.gastro.2023.10.026↗
  5. Maintenance Therapy for Pancreatic Cancer, a New Approach Based on the Synergy between the Novel Agent GP-2250 (Misetionamide) and Gemcitabine. Co-author DOI 10.3390/cancers16142612↗
  6. GP-2250, a novel anticancer agent, inhibits the energy metabolism, activates AMP-Kinase and impairs the NF-kB pathway in pancreatic cancer cells. Co-author DOI 10.1111/jcmm.17825↗
  7. Coinhibition of topoisomerase 1 and BRD4-mediated pause release selectively kills pancreatic cancer via readthrough transcription. Co-author DOI 10.1126/sciadv.adg5109↗
  8. Interactive enhancer hubs (iHUBs) mediate transcriptional reprogramming and adaptive resistance in pancreatic cancer. Co-author DOI 10.1136/gutjnl-2022-328154↗
  9. Identification of a ΔNp63-Dependent Basal-Like A Subtype-Specific Transcribed Enhancer Program (B-STEP) in Aggressive Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1541-7786.mcr-22-0916↗
  10. De novo expression of gastrokines in pancreatic precursor lesions impede the development of pancreatic cancer. Co-author DOI 10.1038/s41388-022-02182-4↗
  11. Functional noninvasive detection of glycolytic pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s40170-022-00298-5↗
  12. TNF-α-producing macrophages determine subtype identity and prognosis via AP1 enhancer reprogramming in pancreatic cancer. Co-author DOI 10.1038/s43018-021-00258-w↗
  13. Functional metabolic phenotyping of human pancreatic ductal adenocarcinoma Co-author DOI 10.1101/2021.07.23.452145↗
  14. Synergistic targeting and resistance to PARP inhibition in DNA damage repair-deficient pancreatic cancer. Co-author DOI 10.1136/gutjnl-2019-319970↗
  15. Characterization of a dual BET/HDAC inhibitor for treatment of pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.33137↗
  16. TFEB-mediated lysosomal biogenesis and lysosomal drug sequestration confer resistance to MEK inhibition in pancreatic cancer. Co-author DOI 10.1038/s41420-020-0246-7↗
  17. A genetic roadmap of pancreatic cancer: still evolving. First author DOI 10.1136/gutjnl-2016-313317↗
  18. Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/nm.3952↗
  19. The miR-17-92 cluster counteracts quiescence and chemoresistance in a distinct subpopulation of pancreatic cancer stem cells. Co-author DOI 10.1136/gutjnl-2014-308470↗
  20. A microRNA-based test improves endoscopic ultrasound-guided cytologic diagnosis of pancreatic cancer. Co-author DOI 10.1016/j.cgh.2014.02.038↗
  21. Induction of pancreatic cancer cell migration by an autocrine epidermal growth factor receptor activation. First author DOI 10.1016/j.yexcr.2014.04.022↗
  22. New insights in the composition of extracellular vesicles from pancreatic cancer cells: implications for biomarkers and functions. Co-author DOI 10.1186/s12953-014-0050-5↗
  23. A soluble form of the giant cadherin Fat1 is released from pancreatic cancer cells by ADAM10 mediated ectodomain shedding. Co-author DOI 10.1371/journal.pone.0090461↗
  24. Norepinephrine inhibits the migratory activity of pancreatic cancer cells. Co-author DOI 10.1016/j.yexcr.2013.04.015↗
  25. Claudin-4-targeted optical imaging detects pancreatic cancer and its precursor lesions. Co-author DOI 10.1136/gutjnl-2012-302577↗
  26. Multimodal Treatment Eliminates Cancer Stem Cells and Leads to Long-Term Survival in Primary Human Pancreatic Cancer Tissue Xenografts. Co-author DOI 10.1371/journal.pone.0066371↗
  27. Global microRNA expression profiling of microdissected tissues identifies miR-135b as a novel biomarker for pancreatic ductal adenocarcinoma. Last author DOI 10.1002/ijc.26466↗
  28. Lack of CCR7 expression is rate limiting for lymphatic spread of pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.26502↗

Closest collaborators

The 25 strongest of 138 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jens Thomas Siveke · 11 shared papers, 2015–2026 · strength 1.36
  2. Marija Trajkovic‐Arsic · 8 shared papers, 2015–2026 · strength 0.96
  3. Elisabeth Heßmann · 8 shared papers, 2015–2026 · strength 0.96
  4. Smiths Lueong · 5 shared papers, 2020–2025 · strength 0.63
  5. Volker Ellenrieder · 5 shared papers, 2015–2026 · strength 0.61
  6. Waldemar H. Uhl · 5 shared papers, 2012–2024 · strength 0.60
  7. Irina Heid · 5 shared papers, 2015–2026 · strength 0.57
  8. Rickmer Braren · 5 shared papers, 2015–2026 · strength 0.57
  9. Steven A. Johnsen · 4 shared papers, 2020–2024 · strength 0.49
  10. Feda H. Hamdan · 4 shared papers, 2020–2024 · strength 0.49
  11. Bence Sipos · 5 shared papers, 2012–2026 · strength 0.43
  12. Phyllis F. Cheung · 4 shared papers, 2020–2023 · strength 0.42
  13. Laura Godfrey · 3 shared papers, 2021–2025 · strength 0.40
  14. Andrea Tannapfel · 5 shared papers, 2012–2023 · strength 0.39
  15. Marie Buchholz · 2 shared papers, 2023–2024 · strength 0.38
  16. Britta Majchrzak‐Stiller · 2 shared papers, 2023–2024 · strength 0.38
  17. Chris Braumann · 2 shared papers, 2023–2024 · strength 0.38
  18. Philipp Höhn · 2 shared papers, 2023–2024 · strength 0.38
  19. Stephano S. Mello · 3 shared papers, 2015–2026 · strength 0.37
  20. Mert Erkan · 3 shared papers, 2015–2026 · strength 0.37
  21. Julien Sage · 3 shared papers, 2015–2026 · strength 0.37
  22. Alexander Herner · 3 shared papers, 2015–2026 · strength 0.37
  23. Roland Michael Schmid · 3 shared papers, 2015–2026 · strength 0.37
  24. Pawel Karol Mazur · 3 shared papers, 2015–2026 · strength 0.37
  25. Iréne Esposito · 3 shared papers, 2015–2026 · strength 0.37

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.